CSL Ltd Annual Report 2021

Product Registrations and Indications 2020/21* Immunology Focus on improved patient convenience, plasma yield improvements, expanded labels, new formulation science, and recombinant technology. Product Type Country/Region ALBURX ® 20/25 Human Albumin NR Bolivia, Honduras, Nicaragua BERINERT ® C1-Esterase Inhibitor Intravenous (Human) 500 IU NR Turkey, Croatia Hepatitis-B-Immunoglobulin P Behring ® 200 IU/ml NR Algeria HIZENTRA ® Immune Globulin Subcutaneous (Human) 20% Liquid NR Turkey PRIVIGEN ® Immune Globulin Intravenous (Human) 10% Liquid NR Ukraine RHOPHYLAC ® 300 Human Anti-D (Rh0) Immunoglobulin NR Ukraine, Bolivia TETAGAM ® Human Tetanus Immunoglobulin NR Hungary HIZENTRA ® Immune Globulin Subcutaneous (Human) 20% Liquid NI Indonesia, Malaysia (CIDP) PRIVIGEN ® Immune Globulin Intravenous (Human) 10% Liquid NI Serbia (MMN) Haematology Maximize the value and performance of our existing coagulation therapies and develop newprotein and gene-based therapies. AFSTYLA ® Coagulation Factor VIII (Recombinant) 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, & 3000 IU NR Russia, Mexico BERIATE ® Coagulation Factor VIII (Human) 500 IU and 1000 IU NR Bolivia COAPLEX ® Prothrombin complex (Human) NR Belarus IDELVIAN Coagulation Factor IX (Recombinant) Albumin Fusion Protein 250 IU, 500 IU, 1000 IU & 2000 IU NR Mexico IDELVION ® albutrepenonacog alfa 3500 IU NR Australia (Line Extension) Respiratory Develop new treatments for respiratory diseases using our existing plasma-derived therapies and novel recombinantmonoclonal antibodies. ZEMAIRA ® Alpha-1 Proteinase Inhibitor (Human) NR Argentina Vaccines Develop products for the prevention of infectious diseases. AFLURIA ® QUAD JUNIOR Influenza Vaccine (inactivated, split virion) NR Argentina (for the prevention of influenza in persons age 6months – less than 3 years) FLUAD ® TETRA Influenza Vaccine, Adjuvanted NR UK FLUAD ® QUAD Influenza Vaccine, Adjuvanted (surface antigen, inactivated) NR NewZealand FLUCELVAX ® QUAD Influenza Vaccine (cell culture) NR Argentina, Switzerland FLUCELVAX ® QUAD Influenza Vaccine (surface antigen, inactivated, cell culture) NR Australia (for the prevention of influenza in persons 9 years and older) FLUCELVAX ® TETRA Influenza Vaccine (surface antigen, inactivated, cell culture) NR UK FOCLIVIA ® Pandemic Influenza A Vaccine (H5N1), Adjuvanted (surface antigen, inactivated) NR Canada AFLURIA ® QUAD Influenza Vaccine (inactivated, split virion) NI Argentina (for the prevention of influenza in persons age 3 years and older) FLUCELVAX ® QUADRIVALENT Influenza Vaccine (cell culture) NI United States (for the prevention of influenza in persons 2 years and older) FLUCELVAX ® QUAD Influenza Vaccine (cell culture) NI Europe (for the prevention of influenza in persons 2 years and older) FLUCELVAX ® QUAD Influenza Vaccine (surface antigen, inactivated, cell culture) NI Canada (for the prevention of influenza in persons 2 years and older) In-LicensedProducts 1, 2 IKERVIS ® (ciclosporin eye drops) for severe keratitis in adult patients with dry eye disease NR Australia REAGILA ® (cariprazine) for the treatment of schizophrenia in adult patients NR Australia * First-time registrations or indications for CSL products in the listed countries/regions over the reporting period. CIDP=chronic inflammatory demyelinating polyneuropathy, MMN=multifocal motor neuropathy, NI=new indication, NR=new registration. 1 IKERVIS ® is a registered trademark of Santen SAS. 2 REAGILA ® is a registered trademark of Gedeon Richter Plc. CSL Limited Annual Report 2020/21 35